<DOC>
	<DOCNO>NCT02989584</DOCNO>
	<brief_summary>The purpose study test safety study drug , atezolizumab , combine standard chemotherapy drug , gemcitabine cisplatin ( GC ) . This study help researcher begin understand whether combine GC atezolizumab well , , bad usual approach use GC alone .</brief_summary>
	<brief_title>A Pilot Safety Study Atezolizumab Combination With Cisplatin + Gemcitabine Pts With Metastatic Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age ≥ 18 year ECOG Performance Status 0 1 Required Initial Laboratory Values within 14 day enrollment : Absolute Neutrophil Count ≥ 1500 cells/mm^3 Lymphocyte count ≥ 300/mm^3 Platelets ≥ 100,000 cells/mm^3 Hemoglobin ≥ 9.0 g/dL Bilirubin ≤ 1.5 upper limit normal ( ULN ) institution For patient know Gilbert 's disease : bilirubin ≤ 3 x ULN Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 3.0 x ULN institution . For patient metastatic cohort document liver bone metastasis : AST and/or ALT ≤ 5.0 x ULN Alkaline phosphatase ≤ 2.5 x ULN institution For patient metastatic cohort document liver bone metastasis : alkaline phosphatase ≤ 5 x ULN Estimated glomerular filtration rate ≥ 60 ml/min/1.73m2 use CKD EPI equation : eGFR = 141 x min ( Scr/k , 1 ) x max ( Scr/k , 1 ) 1.209 x 0.993Age x 1.018 [ female ] x 1.159 [ black ] Scr serum creatinine , k 0.7 female 0.9 male , 0.329 female 0.411 male , min indicate minimum Scr/k 1 , max indicate maximum Scr/k 1 If female childbearing potential , urine pregnancy test negative . INR aPTT ≤ 1.5 x ULN therapeutic anticoagulation . Patients receive therapeutic anticoagulation stable dose . Phase I Cohort Archival tumor specimen must submit prior enrollment . Samples collect fineneedle aspiration , brushing , cell pellet pleural effusion , bone metastasis , lavage acceptable . Acceptable sample include coreneedle biopsy deep tumor tissue ( minimum three core ) excisional , incisional , punch , forceps biopsy cutaneous , subcutaneous , mucosal lesion . If archival tissue use , representative urothelial carcinoma FFPE tumor specimen ( tumor block 30 unstained slide ) must provide . Patients &lt; 30 slide may enrol discussion principal investigator . Primary metastatic specimen may submit . Subject must agree undergo two researchdirected biopsy treatment . The patient must one site measurable disease amenable biopsy , opinion investigator and/or interventional radiologist , likely yield acceptable tumor sample core biopsy per pathology criterion . Life expectancy ≥ 12 week Histologically cytologically confirm locally advance ( T4b , N ; T , N23 ) , metastatic ( M1 ) urothelial carcinoma ( confirm enrol institution ) bladder , ureter , urethra , renal pelvis . Patients mixed histology require predominant urothelial component review pathologist treat institution . Measurable disease per RECIST v1.1 patient solid malignancy Phase 2 Cohort Pathology : Representative urothelial carcinoma FFPE tumor specimen ( tumor block 30 unstained slide ) . Patients &lt; 30 slide may enrol discussion principal investigator . Muscle invasive urothelial carcinoma bladder histologically confirm enrol institution . ( Urothelial carcinoma invade prostatic stroma histologic muscle invasion allow provide extent disease confirm via image and/or EUA . ) Clinical stage T24a ; N0/X ; M0 Medically appropriate candidate radical cystectomy , per MSK participate site Attending Urologic Oncologist Evidence NYHA functional class III IV heart disease Serious intercurrent medical psychiatric illness , include serious active infection Preexisting sensory grade ≥ 2 neuropathy Preexisting grade ≥ 2 hearing loss Major surgical procedure within 28 day prior Cycle 1 , Day 1 anticipation need major surgical procedure course study . Transurethral resection urinary tract diagnostic procedure , excisional biopsy , MediPort placement , NOT define major surgical procedure . Any follow within 6 month prior study drug administration : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident , transient ischemic attack Ongoing cardiac dysrhythmias NCI CTCAE Version 4.0 grade ≥ 2 . However , stable atrial fibrillation control medically device ( e.g . pacemaker ) prior ablation allow . History human immunodeficiency virus ( HIV ) infection acquire immunodeficiency syndrome ( AIDS ) relate illness Concurrent treatment another clinical trial ; supportive care trial nontreatment trial , e.g . QOL , allow Pregnancy , lactation , breastfeed . Patients must surgically sterile , postmenopausal , must agree use effective contraception period therapy 5 month last dose atezolizumab . The definition effective contraception base judgment principal investigator designate associate . Male patient must surgically sterile agree use effective contraception . History autoimmune disease , include limited myasthenia gravis , myositis , autoimmune hepatitis , systemic lupus erythematosus , rheumatoid arthritis , inflammatory bowel disease , Wegener 's granulomatosis , vascular thrombosis associate antiphospholipid syndrome , Sjogren 's syndrome , GuillainBarre syndrome , multiple sclerosis , systemic vasculitis , glomerulonephritis . Patients history autoimmune related hypothyroidism stable dose thyroid replacement hormone may eligible study Patients control Type I diabetes mellitus stable dose insulin may eligible study History idiopathic pulmonary fibrosis , pneumonitis ( include drug induce ) , organize pneumonia ( i.e. , bronchiolitis obliterans , cryptogenic organize pneumonia , etc . ) , evidence active pneumonitis screen chest compute tomography ( CT ) scan History radiation pneumonitis radiation field ( fibrosis ) permit . Patients active hepatitis B virus ( HBV , chronic acute , define positive hepatitis B surface antigen [ HBsAg ] test screening ) hepatitis C antibody Patients past HBV infection resolve HBV infection ( define presence hepatitis B core antibody [ HBc Ab ] absence HBsAg ) eligible . HBV DNA must obtain patient prior Cycle 1 , Day 1 confirm negative . Patients positive hepatitis C virus ( HCV ) antibody eligible polymerase chain reaction negative HCV RNA . Active tuberculosis BCG infection Severe infection within 4 week prior Cycle 1 , Day 1 , include limited hospitalization complication infection , bacteremia , severe pneumonia Signs symptom infection within 2 week prior Cycle 1 , Day 1 . Abnormal urinalysis constitute signs/symptoms infection unless urine culture obtain screen grows ≥ 100,000 colony bacteria . Patients ileal conduit urinalysis and/or culture abnormal eligible unless peripheral blood WBC &gt; ULN , fever , symptom suggestive urinary tract infection . Therapeutic oral IV antibiotic within 2 week prior Cycle 1 , Day 1 Patients receive prophylactic antibiotic ( e.g. , prevention urinary tract infection prevent chronic obstructive pulmonary disease exacerbation ) eligible . Prior allogeneic stem cell solid organ transplant Administration intravesical bacillus CalmetteGuerin ( BCG ) within 4 week Cycle 1 , Day 1 Administration live , attenuate vaccine within 4 week Cycle 1 , Day 1 anticipation live attenuated vaccine require study . Influenza vaccination give influenza season ( approximately October March ) . Patients must receive live , attenuate influenza vaccine ( e.g. , FluMist ® ) within 4 week prior Cycle 1 , Day 1 time study . AEs prior anticancer therapy resolve Grade ≤ 1 except alopecia Bisphosphonate therapy symptomatic hypercalcemia Use bisphosphonate therapy reason ( e.g. , bone metastasis osteoporosis ) allow . Known clinically significant liver disease , include active viral , alcoholic , hepatitis ; cirrhosis ; inherit liver disease Patients history active bone marrow disorder expect interfere study therapy ( e.g . acute leukemia , accelerated/blastphase chronic myelogenous leukemia , chronic lymphocytic leukemia , Burkitt lymphoma , plasma cell leukemia , nonsecretory myeloma ) Known primary central nervous system ( CNS ) malignancy , active untreated CNS metastasis , symptomatic CNS metastasis , and/or leptomeningeal disease Patients eczema , psoriasis , lichen simplex chronicus vitiligo dermatologic manifestation ( e.g. , patient psoriatic arthritis would exclude ) permit provided meet following condition : Patients psoriasis must baseline ophthalmologic exam rule ocular manifestation Rash must cover less 10 % body surface area ( BSA ) Disease well control baseline require low potency topical steroid ( e.g. , hydrocortisone 2.5 % , hydrocortisone butyrate 0.1 % , flucinolone 0.01 % , desonide 0.05 % , aclometasone dipropionate 0.05 % ) No acute exacerbation underlie condition within last 12 month ( require psoralen plus ultraviolet A radiation [ PUVA ] , methotrexate , retinoids , biologic agent , oral calcineurin inhibitor ; high potency oral steroid ) Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication Malignancies disease study within 5 year prior Cycle 1 , Day 1 , exception negligible risk metastasis death expect curative outcome ( adequately treat carcinoma situ cervix , basal squamous cell skin cancer , localize prostate cancer treat surgically curative intent , ductal carcinoma situ treat surgically curative intent ) undergo active surveillance per standardofcare management ( e.g . prostate cancer Gleason score ≤ 6 , prostatespecific antigen [ PSA ] 10 mg/mL , etc ) . MedicationRelated Prior treatment antiPD1 , CTLA4 , antia PDL1 therapeutic antibody pathwaytargeting agent Treatment systemic immunostimulatory agent ( include limit interferon [ IFN ] interleukin [ IL ] 2 ) within 6 week five halflives drug ( whichever short ) prior Cycle 1 , Day 1 Concomitant use another investigational agent and/or treatment investigational agent within 4 week prior Cycle 1 , Day 1 ( within five halflives investigational product , whichever long ) Treatment systemic immunosuppressive medication ( include limit prednisone , cyclophosphamide , azathioprine , methotrexate , thalidomide , antitumor necrosis factor [ antiTNF ] agent ) within 2 week prior Cycle 1 , Day 1 Patients receive acute , lowdose , systemic immunosuppressant medication ( e.g. , onetime dose dexamethasone nausea ) may enrol . The use inhale corticosteroid mineralocorticoid ( e.g. , fludrocortisone ) patient orthostatic hypotension adrenocortical insufficiency allow . History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion protein Known hypersensitivity Chinese hamster ovary cell product component atezolizumab formulation Phase I Cohort Prior chemotherapy immunotherapy metastatic urothelial bladder cancer . Prior neoadjuvant adjuvant chemotherapy first progression &gt; 12 month allow . Any approved anticancer therapy within 3 week prior enrollment follow exception : Palliative radiotherapy bone metastases must complete &gt; 7 day prior baseline image &gt; 21 day prior cycle 1 day 1 treatment . Hormone replacement therapy oral contraceptive permit Administration intravesical bacillus CalmetteGuerin ( BCG ) &gt; 4 week Cycle 1 , Day 1 allow Tumorrelated pain increase baseline 2 week control stable dose opiate Uncontrolled pleural effusion , pericardial effusion , ascites ( indwell drainage catheter allow ) Phase 2 Cohort Prior systemic chemotherapy ( prior intravesical therapy allow ) Prior radiation therapy bladder Any approve anticancer therapy within 3 week prior enrollment Administration intravesical bacillus CalmetteGuerin ( BCG ) &gt; 4 week Cycle 1 , Day 1 allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>bladder cancer</keyword>
	<keyword>metastatic bladder cancer</keyword>
	<keyword>atezolizumab</keyword>
	<keyword>urothelial carcinoma</keyword>
</DOC>